Although ER plays a central role in the prognosis and endocrine therapy responsiveness prediction, ER as a transcription factor can be modulated by various cofactors and be cross interacted with other signal pathways [3-7], which indicates ER is not a perfect index for the treatment of breast cancer. Here, ESR1 is linked to breast cancer.